The Scheltens scale, disability after head injury, and cannabis for multiple sclerosis - a podcast by BMJ Group

This month, we explore the latest research on treating multiple sclerosis with cannabis extract. Editor Matthew Kiernan speaks to John Zajicek, professor of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, UK. (0.54)

Received wisdom is that if you are disabled shortly after a head injury, you are not going to see this improve. However Tom McMillan, professor of Clinical Neuropsychology, University of Glasgow, explains how he has shown long term outcomes are actually dynamic. (9.08)

And the Scheltens scale. If you work with dementia patients you’ve probably used this simple rating of hippocampal atrophy. Philip Scheltens, director of the Alzheimer Center, VU University Medical Center, Amsterdam, talks about how he put the scale together 20 years ago, and why it still underpins practice. (14.21)

See also:

Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial http://tinyurl.com/a7vwezb

Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates http://tinyurl.com/bxlc2dx

Disability in young people and adults after head injury: 12–14 year follow-up of a prospective cohort http://tinyurl.com/albh9k3

Further episodes of JNNP podcast

Further podcasts by BMJ Group

Website of BMJ Group